Chemical Namesacituzumab govitecan-hziy
Dosage FormInjection (intravenous; 180 mg lyophilized powder in single-dose vial)
Drug ClassMonoclonal antibodies
SystemFemale reproductive
CompanyImmunomedics, Inc.
Approval Year2020


  • Indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Trodelvy (sacituzumab govitecan-hziy) Prescribing Information.2020Immunomedics, Inc. Morris Plains, NJ